Corcept Therapeutics reported third quarter 2026 results that significantly outperformed expectations, with total revenue of $340.5 million exceeding the $215.42 million estimate by 58%. The beat was driven by the rapid adoption of the recently launched oncology drug Lifyorli and continued expansion of the core Korlym franchise.
Key Highlights
- Lifyorli product revenue reached $91.4 million in its second full quarter since launch, a 92% increase over the second quarter of 2026.
- Korlym and authorized generic revenue grew to $249.1 million, a 19% sequential increase that alone exceeded the analyst estimate for total company revenue.
- Diluted EPS of $1.01 beat the $0.68 estimate by 48%, while cash and investments increased to $662.3 million despite $43.7 million in stock repurchases during the quarter.